P2RY4 Antibody

What is the difference between polyclonal and monoclonal P2RY4 antibodies, and which should I choose for my experimental design?

Polyclonal P2RY4 antibodies (like those from Abcam and Alomone Labs) recognize multiple epitopes on the receptor, potentially offering stronger signal detection but with greater variability between lots. In contrast, monoclonal antibodies provide consistent lot-to-lot reproducibility but may have weaker signal intensity due to recognizing only a single epitope .

For experiments requiring high specificity and reproducibility (e.g., quantitative analysis across multiple experiments), monoclonal antibodies are preferable. For applications like immunohistochemistry on tissue with low P2RY4 expression, polyclonal antibodies may provide better sensitivity. When selecting antibodies, consider whether they recognize the native conformation, as some P2RY4 antibodies specifically detect only the native form in biochemical and cytometric applications .

How can I properly validate the specificity of P2RY4 antibodies in my experimental system?

Proper validation of P2RY4 antibodies should include:

• Western blot analysis with appropriate controls:

  • Use P2RY4 blocking peptides as negative controls (e.g., P2Y4 Receptor Blocking Peptide #BLP-PR006)

  • Include P2RY4 knockout or knockdown samples when available

  • Expected band size for P2RY4 is approximately 41 kDa

• Immunohistochemistry validation:

  • Perform parallel staining with known positive controls (e.g., astrocytic processes in rat cerebellum)

  • Include negative controls lacking primary antibody

  • Use different antibodies targeting distinct epitopes of P2RY4

  • Evaluate cellular distribution pattern (e.g., P2RY4 appears in astrocytic processes but not in Purkinje neuronal dendrites in rat cerebellum)

• Cross-reactivity assessment:

  • Test antibody against related P2Y receptor subtypes

  • BLAST analysis of the peptide immunogen should show no homology with other proteins

Which epitopes of P2RY4 are commonly targeted by research antibodies, and how does epitope selection affect experimental applications?

P2RY4 antibodies typically target:

• C-terminal epitopes (intracellular domain):

  • Example: Alomone Labs antibody targets residues 337-350 of rat P2RY4

  • Advantageous for Western blotting and immunoprecipitation

  • May not access epitope in non-permeabilized cells

• Extracellular domain epitopes:

  • Suitable for detecting surface expression in live cells

  • Used in flow cytometry and immunocytochemistry of non-permeabilized cells

  • Example: Antibody for extracellular domain available for human and monkey P2RY4

• Internal region epitopes:

  • Synthetic 16 amino acid peptide from internal region of human P2RY4

  • Often requires detergent permeabilization for access

The choice of epitope significantly impacts application suitability. For detecting surface expression in live cells, antibodies targeting extracellular domains are essential. For Western blotting, antibodies against conserved intracellular domains may offer broader cross-species reactivity but require membrane solubilization.

What methodological approaches can improve detection of endogenously expressed P2RY4 in primary tissues?

Detecting endogenous P2RY4 presents significant challenges due to typically low expression levels. Optimization strategies include:

• Antibody affinity enhancement:

  • The R5 mutant antibody with five arginine residues introduced into variable regions showed a 50-fold increase in affinity compared to the original 12-10H antibody, enabling detection of endogenously expressed P2RY4 in microglia isolated from rat models of neuropathic pain

  • This demonstrates the value of charge-based modifications to improve antibody-antigen interactions with anionic regions of P2RY4

• Sample enrichment techniques:

  • Membrane fractionation prior to Western blotting

  • Use of tyramide signal amplification for immunohistochemistry

• Fixation and permeabilization optimization:

  • For immunohistochemistry on primary tissues, test multiple antigen retrieval methods

  • For formalin-fixed, paraffin-embedded tissues, proteinase K antigen retrieval has been successful

  • Heat-induced antigen retrieval has shown efficacy with human pancreatic tissue

• Detection strategy:

  • For microglial cells, permeabilization with 3% saponin improved intracellular staining

  • For flow cytometry, detaching cells by scraping rather than enzymatic methods preserves surface epitopes

How can spatial distribution of P2RY4 be accurately mapped in neural tissues?

Mapping P2RY4 distribution in neural tissues requires specialized approaches:

• Cell-type specific co-localization:

  • Double immunolabeling with cell-type specific markers (e.g., calbindin D28k for Purkinje cells)

  • In rat cerebellum, P2RY4 localizes to astrocytic processes but is absent from Purkinje neuronal dendrites

• Subcellular localization techniques:

  • Super-resolution microscopy with membrane markers

  • Electron microscopy with immunogold labeling

  • Confocal z-stack imaging with optical sectioning

• Validation with genetic approaches:

  • Correlation of antibody staining with fluorescent protein-tagged P2RY4 expression

  • RNA in situ hybridization to correlate protein with mRNA expression

• Tissue preparation considerations:

  • Fresh frozen versus fixed tissues demonstrate different preservation of epitopes

  • For formalin-fixed sections, optimize antigen retrieval through heat, enzymatic, or pH-based methods

What strategies enable functional correlation between P2RY4 expression and physiological responses in experimental models?

To correlate P2RY4 expression with function:

• Combined electrophysiology and immunocytochemistry:

  • Patch-clamp recording followed by single-cell immunostaining

  • Correlation of UTP-induced currents with P2RY4 expression levels

• In vivo models with genetic manipulation:

  • P2RY4 knockout mice exhibit protection against myocardial infarction, increased adiponectin secretion, and decreased cardiac inflammation under ischemic conditions

  • Transgenic expression of mutant forms (e.g., loss-of-function N178T variant)

• Calcium imaging with immunocytochemistry:

  • Measure UTP-induced calcium responses followed by P2RY4 immunostaining

  • Correlation of response magnitude with receptor expression level

• Functional assays with quantitative expression analysis:

  • Chloride secretion measurements in gastrointestinal tissues

  • Quantification of amyloid precursor protein production in neuronal cultures

What are the key differences between human and rodent P2RY4 receptors that impact antibody selection and experimental design?

Important species differences in P2RY4 include:

• Pharmacological profile:

  • Human P2RY4 is highly selective for UTP

  • Rat P2RY4 responds equally to both UTP and ATP, as well as other triphosphate nucleotides like Ap4A

  • These differences may affect functional validation experiments

• Sequence homology considerations:

  • Based on sequence identity, antibodies raised against human P2RY4 may show varied reactivity:

    • Expected reactivity in monkey (94%), primate (100%)

    • Moderate reactivity in mouse, rat, bat, porcine (81%)

    • Variable reactivity in bovine and opossum (88%)

• Epitope-specific differences:

  • C-terminal epitopes may show greater conservation across species

  • Extracellular domains typically display greater sequence divergence

• Functional role variations:

  • In mice, P2RY4 knockout protects against myocardial infarction and improves insulin sensitivity through adiponectin

  • Human P2RY4 loss-of-function N178T variant associates with less severe coronary atherosclerosis and lower fasting plasma glucose

These differences necessitate careful antibody selection for cross-species studies, with validation in each target species.

How should antibody validation differ when studying P2RY4 in human clinical samples versus rodent experimental models?

For human clinical samples:

• Validation recommendations:

  • Use human cell lines with confirmed P2RY4 expression (e.g., K562 cells)

  • Implement peptide competition assays with human-specific blocking peptides

  • Include appropriate negative controls (tissues known to lack P2RY4)

  • Perform siRNA knockdown in human cell lines as specificity controls

• Clinical sample considerations:

  • Optimize protocols for formalin-fixed, paraffin-embedded tissues common in clinical settings

  • Account for potential post-mortem changes in receptor integrity

  • Consider effects of various fixatives on epitope preservation

For rodent models:

• Validation requirements:

  • Use tissues from P2RY4 knockout mice as negative controls

  • Validate in primary cells (e.g., microglia isolated from rat spinal cord)

  • Test reactivity in transfected cells overexpressing rodent P2RY4

• Model-specific adaptations:

  • For neuropathic pain models, validate antibodies specifically in spinal cord microglia

  • For cardiovascular studies, confirm detection in cardiac tissue from appropriate models

How are P2RY4 antibodies being utilized to investigate neuropathic pain mechanisms?

P2RY4 antibodies are instrumental in neuropathic pain research through:

• Detection of upregulated expression:

  • In animal models of neuropathic pain, P2RY4 is selectively upregulated in spinal cord microglia

  • Enhanced antibodies (e.g., R5 mutant) with improved affinity enable detection of endogenously expressed P2RY4 in microglia isolated from rats with spinal nerve injury

• Cellular localization studies:

  • P2RY4 antibodies help determine cellular distribution in dorsal horn and dorsal root ganglia

  • Co-labeling with microglial markers confirms cell-type specific expression

• Functional correlation experiments:

  • Immunohistochemistry paired with behavioral assessments in pain models

  • Correlating receptor expression levels with electrophysiological responses to UTP

• Treatment response monitoring:

  • Evaluating changes in P2RY4 expression following pharmacological interventions

  • Assessing receptor internalization and trafficking using surface versus intracellular staining

What methodological considerations are important when using P2RY4 antibodies to study cardiovascular pathologies?

When investigating P2RY4 in cardiovascular disease:

• Model-specific validation:

  • In coronary artery disease patients, P2RY4 variants (particularly N178T) associate with less severe coronary artery atherosclerosis and lower fasting plasma glucose

  • In P2RY4 knockout mice, protection against myocardial infarction correlates with increased adiponectin secretion and decreased cardiac inflammation

• Cell-specific detection protocols:

  • For vascular smooth muscle cells, where P2RY4 is expressed at lower levels

  • For cardiac tissues, where inflammation may affect antibody penetration

• Functional correlation approaches:

  • Relating P2RY4 expression to ET-1 (a P2RY4 target gene involved in cardiac ischemia)

  • Assessing receptor levels in relation to cardiac permeability and neutrophil infiltration

• Tissue preparation considerations:

  • For human samples, standardize fixation protocols to maintain epitope integrity

  • For animal models, consider perfusion fixation for optimal antibody penetration

What experimental designs best utilize P2RY4 antibodies to investigate potential roles in neurodegenerative disorders?

For neurodegenerative disease research:

• Alzheimer's disease studies:

  • P2RY4 regulates amyloid precursor protein (APP) production in the brain

  • P2RY4 functions as a receptor for "drink me" signals (ATP) that mediate microglial uptake of soluble amyloid beta peptide 1-42

• Recommended experimental approaches:

  • Co-localization with disease markers (e.g., amyloid plaques, phosphorylated tau)

  • Sequential immunohistochemistry on human post-mortem tissue

  • Age-dependent expression analysis in transgenic animal models

• Functional assessment techniques:

  • Microglia-specific expression analysis in disease models

  • P2RY4 expression correlation with microglial phagocytic activity

  • Receptor trafficking studies under inflammatory conditions

• Technical considerations:

  • Autofluorescence quenching for aged brain tissue

  • Antigen retrieval optimization for heavily fixed tissues

  • Detergent selection to maintain membrane protein structure

What are the most common causes of inconsistent P2RY4 antibody performance, and how can they be systematically addressed?

Common challenges with P2RY4 antibodies include:

• Epitope masking issues:

  • Membrane proteins like P2RY4 may have epitopes obscured by lipid environment

  • Solution: Test multiple detergents for membrane solubilization (e.g., Triton X-100, CHAPS, digitonin)

  • For fixed tissues, extend antigen retrieval times or try multiple methods

• Antibody dilution optimization:

  • Reported working dilutions vary widely:

    • 1/300 for Western blot of rat brain membranes

    • 1/500 for Western blot of K562 cell extracts

    • 1/50 for IHC of human lung cancer tissue

  • Solution: Perform systematic dilution series for each application and tissue

• Storage and handling issues:

  • P2RY4 antibodies can be stored undiluted at 4°C for up to 1 month

  • For longer storage, keep as concentrated solution at -20°C or below

  • Avoid multiple freeze-thaw cycles

  • Aliquot antibodies upon receipt to minimize degradation

• Fixation artifacts:

  • Formalin fixation can mask epitopes

  • Test alternative fixatives (e.g., acetone, methanol, or paraformaldehyde)

  • For FFPE tissues, optimize proteinase K or heat-induced antigen retrieval

What specialized techniques can enhance detection of low-abundance P2RY4 in complex tissue samples?

For improved detection of low-abundance P2RY4:

• Signal amplification methods:

  • Tyramide signal amplification can increase sensitivity 10-100 fold

  • Biotin-streptavidin systems (validated for P2RY4 detection using biotinylated secondary antibody followed by alkaline phosphatase-streptavidin)

• Sample enrichment approaches:

  • Membrane fractionation prior to Western blotting

  • Immunoprecipitation followed by immunoblotting

  • Use of BSA-free antibody formulations to reduce background (e.g., NBP3-14439)

• Enhanced visualization strategies:

  • Confocal microscopy with spectral unmixing to distinguish signal from autofluorescence

  • Super-resolution microscopy for precise subcellular localization

  • Digital amplification through computational image processing

• Improved antibody technologies:

  • Enhanced affinity antibodies like the R5 mutant (50-fold higher affinity than original antibody)

  • Recombinant nanobodies with optimized binding properties

Table 1: Comparative Analysis of P2RY4 Antibody Applications

Table 2: Species Cross-Reactivity of P2RY4 Antibodies